How Investors Are Reacting To Abbott (ABT) Dual Glucose‑Ketone Libre Duo FDA Greenlight

Abbott Nutrition agreed to pay $670 million to resolve claims related to its preterm infant formulas, without admitting liability. The settlement includes a Missouri case where a jury awarded $495 million to a plaintiff. Abbott maintains its products are safe and supported by medical professionals. Separately, Abbott challenged competitor Kendamil's advertising claims, with NAD recommending Kendamil remove certain claims about nutritional benefits.

The FDA approved Abbott Laboratories' Libre Duo 10 Day, a wearable device that continuously monitors both glucose and ketone levels. This first-of-its-kind tracker aims to prevent life-threatening emergencies like diabetic ketoacidosis (DKA) by providing real-time data. Abbott claims the device simplifies monitoring for diabetes patients, who previously had to use separate tests for ketones.

Abbott Laboratories (ABT) received FDA approval for its Libre Duo 10 Day sensor, which tracks glucose and ketone levels. The company's stock closed at $112.47, with mixed returns over different periods. Analysts suggest ABT is 5.6% undervalued, with a fair value of $119.13, citing innovation in high-margin segments. However, investors should monitor diagnostic pricing in China and potential litigation risks.

The Trump administration may add two FDA deputy commissioner roles. FDA approved first-of-kind treatments from Revolution Medicines (Rasonque for pancreatic cancer), Priovant Therapeutics (Lisraya for dermatomyositis), and Janssen Biotech (Imaavy for wAIHA). Abbott's Libre Duo 10 Day received de novo authorization for a dual glucose and ketone monitoring system. FDA issued alerts for Abiomed, Medtronic, and Boston Scientific devices, and recalls for Boston Scientific and AVID Medical products.

Abbott (NYSE:ABT) received FDA authorization for Libre Duo, the first wearable to monitor glucose and ketones. The company plans a U.S. launch in 2026, targeting 8 million users. Abbott's stock is down 11% year-to-date, while competitor Dexcom (NASDAQ:DXCM) is up 34%. Abbott trades at a forward P/E of 21x with a $120.20 analyst target. Reimbursement expansion could drive growth, according to CEO Robert Ford.

Abbott Laboratories (NYSE: ABT) received FDA De Novo authorization for Libre Duo, a wearable that monitors glucose and detects rising ketone levels. The company plans a U.S. launch in 2026. Abbott's stock is down 11.29% over the past year but up 9.2% over the past month. The FDA approval is a regulatory milestone but may not immediately impact revenue.